Table 2.

Estimated biliary excretion pharmacokinetic parameters of Rho-123 (0.2 mg/kg, i.v.) in rats. Five groups were established in both studies: sham RT + Rho-123 (0.2 mg/kg, i.v.); concurrent regimen, RT_2Gy + Rho-123 (0.2 mg/kg, i.v.) 10 min later; sequential regimen, RT_2Gy + Rho-123 (0.2 mg/kg, i.v.) 24 hr later; concurrent regimen, RT_9Gy + Rho-123 (0.2 mg/kg, i.v.) 10 min later; and sequential regimen, RT_9Gy + Rho-123 (0.2 mg/kg i.v.) 24 hr later. The data are expressed as the mean ± SEM values (n = 6 per group).

Pharmacokinetic parameter	Rho-123 (0.2 mg/kg)	RT2Gy		RT9Gy
		After 10 min + Rho-123 (0.2 mg/kg)	After 24 hr +Rho-123 (0.2 mg/kg)	After 10 min + Rho-123 0.2 mg/kg	After 24 hr + Rho-123 (0.2 mg/kg)
AUC0-T (min*µg/mL)	112.64 ± 23.51	190.38 ± 63.61a	115.23 ± 33.31b,g	162.42 ± 38.13c,e	99.48 ± 27.16d,f,h
Cmax (µg/mL)	2.01 ± 0.60	3.56 ± 1.93	2.24 ± 0.57	2.86 ± 0.83	2.07 ± 0.75
Tmax (min)	14 ± 4	11 ± 5	9 ± 5	11 ± 5	13 ± 4
t½ (min)	42 ± 13	46 ± 13	32 ± 8	43 ± 6	34 ± 9
Cl (mL/min/kg)	1.56 ± 0.30	0.92 ± 0.23	1.73 ± 0.61	1.07 ± 0.33	1.91 ± 0.56
MRT (min)	61 ± 14	66 ± 24	47 ± 12	66 ± 8	50 ± 13

AUC, area under the concentration vs. time curve; Tmax, the time at which Cmax is observed; Cmax, peak plasma concentration of the drug after administration.

^aRT_2Gy (wait 10 min) + Rho-123 (0.2 mg/kg) vs. Rho-123 (0.2 mg/kg) only, p = 0.013.

^bRT_2Gy (wait 24 hr) + Rho-123 (0.2 mg/kg) vs. Rho-123 (0.2 mg/kg) only, p = 0.877.

^cRT_9Gy (wait 10 min) + Rho-123 (0.2 mg/kg) vs. Rho-123 (0.2 mg/kg) only, p = 0.018.

^dRT_9Gy (wait 24 hr) + Rho-123 (0.2 mg/kg) vs. Rho-123 (0.2 mg/kg) only, p = 0.391.

^eRT_2Gy (wait 10 min) + Rho-123 (0.2 mg/kg) vs. RT_9Gy (wait 10 min) + Rho-123 (0.2 mg/kg), p = 0.424.

^fRT_2Gy (wait 24 hr) + Rho-123 (0.2 mg/kg) vs. RT_9Gy (wait 24 hr) + Rho-123 (0.2 mg/kg), p = 0.436.

^gRT_2Gy (wait 10 min) + Rho-123 (0.2 mg/kg) vs. RT_2Gy (wait 24 hr) + Rho-123 (0.2 mg/kg), p = 0.047.

^hRT_9Gy (wait 10 min) + Rho-123 (0.2 mg/kg) vs. RT_9Gy (wait 24 hr) + Rho-123 (0.2 mg/kg), p = 0.017.